Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 4(57), p. 1952-1956, 2013

DOI: 10.1128/aac.02084-12

Links

Tools

Export citation

Search in Google Scholar

Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C.

Journal article published in 2013 by Rachel Ulferts, Lonneke van der Linden, L. van der Linden, Hendrik Jan Thibaut ORCID, Kjerstin Hw W. Lanke, Pieter Leyssen, Bruno Coutard, Armando M. De Palma, A. M. De Palma, Bruno Canard ORCID, Johan Neyts ORCID, Frank Jm M. van Kuppeveld, F. J. M. van Kuppeveld
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Although the genus Enterovirus contains many important human pathogens, there is no licensed drug for either the treatment or the prophylaxis of enterovirus infections. We report that fluoxetine (Prozac)—a selective serotonin reuptake inhibitor—inhibits the replication of human enterovirus B (HEV-B) and HEV-D but does not affect the replication of HEV-A and HEV-C or human rhinovirus A or B. We show that fluoxetine interferes with viral RNA replication, and we identified viral protein 2C as the target of this compound.